drugset / Trial / NCT06853444
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.
Timeline
- Start
- 2025-05-08
- Primary completion
- 2026-03-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESG206 | Monoclonal antibody | — | Intravenous |